Treatment of patients with neuropathy and anti-MAG IgM M-proteins

Ann Neurol. 1988 Jul;24(1):93-7. doi: 10.1002/ana.410240118.

Abstract

Five patients with neuropathy and IgM M-proteins that reacted with myelin-associated glycoprotein (MAG) were treated for 10 to 20 months with cytostatic agents. In 2 patients, a decrease in serum M-protein and in anti-MAG IgM levels coincided with a progressive improvement of neuropathy. No clinical improvement and no decrease of anti-MAG IgM were observed in the other patients. The close relationship between the decrease of anti-MAG M-proteins and clinical improvement in these patients supports the pathogenetic role of the M-protein in the neuropathy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Autoantibodies / analysis*
  • Blood Proteins / analysis*
  • Chlorambucil / therapeutic use
  • Cyclophosphamide / therapeutic use
  • Humans
  • Immunoglobulin M / analysis*
  • Immunoglobulins*
  • Male
  • Middle Aged
  • Myelin Proteins / immunology*
  • Myelin-Associated Glycoprotein
  • Neuromuscular Diseases / drug therapy*
  • Neuromuscular Diseases / immunology*
  • Peripheral Nervous System Diseases / drug therapy*
  • Peripheral Nervous System Diseases / immunology
  • Prednisone / therapeutic use

Substances

  • Antineoplastic Agents
  • Autoantibodies
  • Blood Proteins
  • Immunoglobulin M
  • Immunoglobulins
  • M-proteins (Myeloma)
  • Myelin Proteins
  • Myelin-Associated Glycoprotein
  • Chlorambucil
  • Cyclophosphamide
  • Prednisone